Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Journal of Pathology and Translational Medicine
;
: 347-353, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-786131
ABSTRACT
BACKGROUND:
Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples.METHODS:
Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS <1%, 1%–49%, and ≥50%.RESULTS:
The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type.CONCLUSIONS:
Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Inmunohistoquímica
/
Variaciones Dependientes del Observador
/
Muerte Celular
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inmunoterapia
Tipo de estudio:
Estudio pronóstico
Idioma:
Inglés
Revista:
Journal of Pathology and Translational Medicine
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS